Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, May 19, 2013
Technology Networks
 
Register | Sign in
Home Page
  News
Return to the previous page

DNA Sequencing Lays Foundation for Personalized Cancer Treatment

Published: Monday, April 02, 2012
Last Updated: Monday, April 02, 2012
Bookmark and Share
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology to identify mutations at the root of a patient's tumor and to map the genetic evolution of disease and monitor response to treatment.

Full access to this article is for registered users only.
Registration is free-of-charge and allows access to all content on our web communities.

Already registered? Then please log in at the top of the page.

Print Page

Scientific News
Results of the ROTAVAC Rotavirus Vaccine Study in India
Statement of Anthony S. Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases National Institutes of Health.
Vince and Associates Clinical Research Joins the Altasciences Group
The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Redx Pharma Opens £10.5 Million R&D Centre in UK
Liverpool-based drug discovery and development company Redx Pharma is to open a new research and development facility at AZ's Alderley Park site in Cheshire.
NIH Clinical Trial Begins for Treatment of Rare, Fatal Neurological Disorder
Government, industry, academia, and patient groups collaborate on Niemann-Pick Type C research.
NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial
The trial results appeared in the April 1 issue of the Journal of Infectious Diseases.
Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.
Genticel Announces Positive Data from Phase I Trial in HPV Infected Women
First ever trial to recruit HPV infected women with no cervical lesions.
Nanosponges can Remove Toxins from Bloodstream
Engineers have invented a “nanosponge” capable of safely removing a broad class of dangerous toxins from the bloodstream.
Results from C3BS C-CURE® Trial Published in the Journal of the ACC
Trial demonstrates statistically significant improvements in heart function and exercise tolerance with cardiopoietic stem cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net